Glenmark Pharmaceuticals is set to enter the final stage of clinical trials for its new drug, Revamilast, across several countries this year. It is meant for treatment of inflammatory disorders like asthma and rheumatoid arthritis. Glenmark may soon seek approval for Phase-III trials in the US, UK and India.
“Glenmark plans to file an IND (Investigational New Drug application) for Revamilast in the US in the third quarter of the current financial year. The company intends to initiate Phase-III trials for at least one indication by the end of FY13,” chairman and managing director Glenn Saldanha told Business Standard.